ADC Therapeutics (ADC Therapeutics) Debt-to-Equity

: -0.84 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

ADC Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.47 Mil. ADC Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $122.91 Mil. ADC Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-148.25 Mil. ADC Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.84.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ADC Therapeutics's Debt-to-Equity or its related term are showing as below:

ADCT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.84 Med: 0.13 Max: 1.48
Current: -0.84

During the past 8 years, the highest Debt-to-Equity Ratio of ADC Therapeutics was 1.48. The lowest was -0.84. And the median was 0.13.

ADCT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ADCT: -0.84

ADC Therapeutics Debt-to-Equity Historical Data

The historical data trend for ADC Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.05

0.13

0.84

1.48

-0.84

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																1.48	3.26	-14.39	-2.28	-0.84

Competitive Comparison

For the Biotechnology subindustry, ADC Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADC Therapeutics Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's Debt-to-Equity falls into.

ADC Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ADC Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.467	+	122.91)	/	-148.249
	=	-0.84

ADC Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.467	+	122.91)	/	-148.249
	=	-0.84

ADC Therapeutics (NYSE:ADCT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ADC Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.